Jun 2026 (Q2 FY26) — Aug 10, 2026
Insight Molecular Diagnostics Q2 FY26 — GraftAssureDx FDA Authorization Nearing & Market Expansion
Read the full callInsight Molecular Diagnostics (IMDX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Insight Molecular Diagnostics earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.24 | −53.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -4770.7 | −2870.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -11.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$3.06 +9.68% · +$0.27
Performance −25.0% 1Y
1Y: $4.08 on 14 Oct 2025 → $3.06. High $8.48 (12 Nov 2025), low $2.55 (30 Mar 2026).
- Previous close
- $2.79
- 52-week range
- $2.55 – $8.48
- One year
- −28.84%
Overview
- Symbol
- IMDX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Insight Molecular Diagnostics earnings calls (IMDX)
Financials
What the filings say
Net profit, year on year: −16% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 2 | 1 | 0 | 1 | 0 | 0 |
| Operating profit | -14 | -34 | -7 | -10 | -11 | -23 | -4 | -11 |
| Operating margin | −11752.2% | −2262.9% | −318.0% | −1900.0% | −4249.2% | −2057.5% | −13790.6% | −4770.7% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -13 | -34 | — | — | — | — | — | — |
| Tax rate | 0.0% | 0.0% | — | — | — | — | — | — |
| Net profit | -13 | -34 | -7 | -10 | -11 | -23 | -4 | -11 |
| EPS ($ per share) | -0.98 | — | -0.26 | -0.30 | -0.34 | — | -0.12 | -0.31 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 75 | 125 | 157 | 253 | 295 | 310 | 338 | 369 |
| Reserves | -71 | -94 | -124 | -188 | -261 | -290 | -351 | -401 |
| Total liabilities | 6 | 9 | 22 | 94 | 60 | 49 | 47 | 57 |
| Fixed assets | 1 | 4 | 4 | 7 | 9 | 5 | 6 | 6 |
| Total assets | 10 | 40 | 55 | 160 | 100 | 75 | 35 | 26 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12 | -20 | -26 | -36 | -46 | -23 | -21 | -22 |
| Cash from investing | -0 | -12 | -12 | -14 | -4 | -1 | -1 | -3 |
| Cash from financing | 12 | 48 | 23 | 78 | 36 | 12 | 20 | 28 |
| Net cash flow | 0 | 16 | -15 | 28 | -14 | -12 | -1 | 3 |
| Capital expenditure | -0 | -1 | -1 | -2 | -4 | -0 | -1 | -3 |
| Free cash flow | -12 | -21 | -27 | -38 | -50 | -24 | -21 | -25 |
Insider filings
28 filings between Oct 31, 2025 and Jul 1, 2026.
Open market
decisions to buy or sellPurchases
$5.69M
14 purchases by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 3
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 7
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | $5.69M | — | Apr 27, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 1, 2026 | Last Andrew J. Director | Tax withheld | 7,700 | $43.8K |
| Jul 1, 2026 | Arno Andrew Director | Tax withheld | 12,100 | $68.8K |
| Jul 1, 2026 | SILVERMAN LOU Director | Tax withheld | 7,700 | $43.8K |
| Jun 11, 2026 | Arno Andrew Director | Award | 32,331 | $0 |
| Jun 11, 2026 | Last Andrew J. Director | Award | 26,943 | $0 |
| Jun 11, 2026 | SILVERMAN LOU Director | Award | 26,943 | $0 |
| Apr 27, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Apr 27, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 250,923 | $913.1K |
| Apr 24, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 38,880 | $137.1K |
| Apr 24, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Apr 23, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 280,381 | $982.0K |
| Apr 23, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Apr 20, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 40,690 | $158.0K |
| Apr 20, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Apr 17, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 40,114 | $143.3K |
| Apr 17, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Apr 16, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 102,057 | $351.7K |
| Apr 16, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Mar 26, 2026 | Riggs Josh CEO and President | Option exercise | 47,170 | — |
| Mar 26, 2026 | Riggs Josh CEO and President | Tax withheld | 12,310 | $50.6K |
| Mar 26, 2026 | Liu James Yang VP ACCT, Cntlr, Treasurer, PAO | Option exercise | 6,289 | — |
| Mar 26, 2026 | Liu James Yang VP ACCT, Cntlr, Treasurer, PAO | Tax withheld | 2,578 | $10.6K |
| Mar 26, 2026 | James Andrea S. Chief Financial Officer | Option exercise | 28,302 | — |
| Mar 26, 2026 | James Andrea S. Chief Financial Officer | Tax withheld | 11,298 | $46.4K |
| Feb 10, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Feb 10, 2026 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 521,739 | $3.00M |
| Oct 31, 2025 | James Andrea S. Chief Financial Officer | Tax withheld | 12,175 | $73.2K |
| Oct 31, 2025 | James Andrea S. Chief Financial Officer | Option exercise | 50,000 | $0 |
| Jul 1, 2025 | Last Andrew J. Director | Award | 35,000 | $0 |
| Jul 1, 2025 | SILVERMAN LOU Director | Award | 35,000 | $0 |
| Jul 1, 2025 | Arno Andrew Director | Award | 55,000 | $0 |
| Feb 7, 2025 | SMITH PATRICK W 10% owner | Other | 385,814 | $790.9K |
| Feb 7, 2025 | SMITH PATRICK W 10% owner | Purchase | 1,077,600 | $2.21M |
| Feb 7, 2025 | James Andrea S. Chief Financial Officer | Purchase | 97,561 | $200.0K |
| Feb 6, 2025 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 660,207 | $1.35M |
| Feb 6, 2025 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Feb 6, 2025 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 4,505,488 | $9.24M |
| Feb 6, 2025 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
| Feb 4, 2025 | SMITH PATRICK W 10% owner | Purchase | 25 | $51 |
| Jan 31, 2025 | SMITH PATRICK W 10% owner | Purchase | 890 | $1.8K |
| Jan 30, 2025 | SMITH PATRICK W 10% owner | Purchase | 318 | $639 |
| Jan 29, 2025 | SMITH PATRICK W 10% owner | Purchase | 3,880 | $7.8K |
| Jan 14, 2025 | SMITH PATRICK W 10% owner | Purchase | 100 | $208 |
| Jan 14, 2025 | SMITH PATRICK W 10% owner | Purchase | 10,286 | $22.1K |
| Jan 13, 2025 | SMITH PATRICK W 10% owner | Purchase | 5,669 | $11.8K |
| Dec 26, 2024 | SMITH PATRICK W 10% owner | Purchase | 90,219 | $192.2K |
| Dec 26, 2024 | Arno Andrew Director | Purchase | 12,500 | $26.4K |
| Dec 5, 2024 | James Andrea S. Chief Financial Officer | Purchase | 20,000 | $45.8K |
| Oct 2, 2024 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 1,315,339 | $3.88M |
| Oct 2, 2024 | BROADWOOD PARTNERS, L.P. 10% owner | Purchase | 0 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Insight Molecular Diagnostics Inc.
Free account. Everything above stays public.
Write why you follow Insight Molecular Diagnostics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading